Furthermore, the signaling pathways related to these effects, mainly JAK/STAT and PI3K/Akt, and MAPK, have been extensively studied in prolactinomas and other tumors as therapeutic targets. Here, SOAT1 is linked to prolactin-producing pituitary gland adenoma.